Anbio Biotechnology (NASDAQ:NNNN) Stock Price Up 5.6% - Still a Buy?

Key Points

• Anbio Biotechnology (NASDAQ:NNNN) shares jumped 5.6% to $24.5050 on Friday (intraday high $25.10) with roughly 24,762 shares traded, about 57% below its average daily volume of 57,502.
• Weiss Ratings upgraded the stock from a sell (d+) to a hold (c-), and MarketBeat shows a consensus Hold rating.
• The company last reported quarterly EPS of $0.04 on revenue of $2.29 million, and its 50-day moving average is $23.63.

Anbio Biotechnology (NASDAQ:NNNN - Get Free Report)'s share price was up 5.6% on Friday . The company traded as high as $25.10 and last traded at $24.5050. Approximately 24,762 shares traded hands during trading, a decline of 57% from the average daily volume of 57,502 shares. The stock had previously closed at $23.20.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings upgraded Anbio Biotechnology from a "sell (d+)" rating to a "hold (c-)" rating in a research note on Monday, February 9th. One research analyst has rated the stock with a Hold rating, Based on data from MarketBeat, the stock presently has a consensus rating of "Hold".

Anbio Biotechnology Trading Up 3.1%

The business's 50-day moving average price is $23.63.

Anbio Biotechnology (NASDAQ:NNNN - Get Free Report) last released its earnings results on Tuesday, December 30th. The company reported $0.04 earnings per share (EPS) for the quarter. The business had revenue of $2.29 million for the quarter.

Anbio Biotechnology Company Profile

Anbio Biotechnology is dedicated to the advancement of medical technology and the provision of in vitro diagnostics (IVD) products. Our unwavering commitment lies in transforming the diagnostics landscape on a global scale, fostering a paradigm shift towards personalized and decentralized diagnostic solutions. By doing so, we aim to significantly enhance patient prognosis and contribute to the betterment of healthcare worldwide. At Anbio Biotechnology, our extensive portfolio comprises an array of IVD products designed to cater to diverse diagnostic needs.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.